1S.A. Mohamedi,J.M. Brewer,J. Alexander. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems[J].Vaccine,2000,(18):2083-2094.
2M.J. Pearse.,D. Drane. ISCOMATRIXTM adjuvant:a potentin ducer of humoral and cellular immune responses[J].Vaccine,2004,(22):2391-2395.
3Margaretha Johansson, Karin Loe vgren-Bengtsson. Iscoms with different quillaja saponin components differ in their immunomodulating activities[J]. Vaccine, 1999,(17):2894-2900.
4Karin Lovgren Bengtsson, Anders Sjolandcr. Adjuvant activity of iscoms;effect of ratio and co-incorporation of antigen and adjuvan[J].Vaccine, 1996,(14):753-760.
9Elizabeth Furrie,Rosemary E. Smith b,Mac W. Turner, Induction of local innate immune responses and modulation of antigen uptake as mechanisms underlying the mucosal adjuvant properties of immune stimulating complexes (ISCOMS)[J].Vaccine,2002,(20): 2254-2262.
3Frederick M, Roger Brent, Robert E, et al . Current protocols in molecular biology[ M], Greene publishing Associates and wiley-Interscience. 1987,10(2) : 10.1.1.
4Christensen L S. High frequency intergenomic recombination of suid herpesvirus( HSV-I, Aujeszky' s disease virus) [J]. Arch Virol, 1993,132:137-150.
5Morein,B, Belak,T, Soos,T, et al . Iscom of viral envelope proteins protects against Aujeszky' s disease[J]. Vet Microbiol. 1989,20(2) : 143-154.
